LYTGOBI 4 mg, film-coated tablet 35 tablets
Active ingredients: Futibatinib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet35 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LYTGOBI 4 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polychlortrifluoroéthylène aluminium de 35 comprimé(s)
- Marketing authorisation holder
- TAIHO PHARMA NETHERLANDS (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 1 Aug 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68552628CIP73027660CIP133400930276600Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUTIBATINIBcomprimé | 4 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.